Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Valeant Pharmaceuticals Intl Inc    VRX   CA91911K1021

VALEANT PHARMACEUTICALS INTL INC (VRX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Valeant Pharmaceuticals Intl : An Application for the Trademark "THERMAGE" Has Been Filed by Valeant Pharmaceuticals

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/08/2018 | 09:57pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "THERMAGE" by Robert Gorman, representing Valeant Pharmaceuticals. This application was made available to the public on February 28, 2018 (see also Valeant Pharmaceuticals).

The serial number for this application is 87356177.

The international trademark goods and services class code for this trademark application is 005. The applicant indicates that "Color is not claimed as a feature of the mark. The mark consists of thermage in lowercase stylized lettering with a line drawing of a lotus flower above the last three letters of the word 'THERMAGE'."

As submitted by the applicant, this trademark application relates to the following goods and services: Dressings for wounds; medicated skin care preparations.

The owner/registrar information for this application is: Robert Gorman, Valeant Pharmaceuticals, Law Department, 1400 N. Goodman Street, Rochester NY 14609.

Keywords for this news article include: Pharmaceutical Companies, Valeant Pharmaceuticals, Business, Trademarks, Health and Medicine.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

(c) 2018 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VALEANT PHARMACEUTICALS IN
06/20VALEANT PHARMACEUTICALS INTL : FDA Hits Valeants Plaque Psoriasis Drug with a Co..
AQ
06/18VALEANT PHARMACEUTICALS INTL : FDA Issues Complete Response Letter For DUOBRII&t..
PR
06/18VALEANT PHARMACEUTICALS INTL : Bausch + Lomb Launches Soothe Xtra Protection Pre..
AQ
06/14VALEANT PHARMACEUTICALS INTL : Argentum Pharmaceuticals Wins Patent Invalidation..
AQ
06/14BAUSCH + LOMB : Launches Soothe® Xtra Protection Preservative Free Lubricant Eye..
PR
06/13VALEANT PHARMACEUTICALS INTL : Rises
AQ
06/12VALEANT PHARMACEUTICALS INTL : Announces News, Hits 52-Week High
AQ
06/12BAUSCH + LOMB : Introduces Ocuvite® Blue Light Eye Vitamins
PR
06/11VALEANT PHARMACEUTICALS INTL INC : Today's Research Reports on Trending Tickers:..
AC
06/09VALEANT PHARMACEUTICALS INTL : Securities Class Action Filed on Behalf of Person..
BU
More news
News from SeekingAlpha
06/20YOUR DAILY PHARMA SCOOP : TG Therapeutics Phase 2 Results, Geron Positive, Agio .. 
06/18FDA rejects Valeant's application for psoriasis lotion Duobrii; shares down 5.. 
06/15Key events next week - healthcare 
06/12Will The Rite Aid - Albertsons Merger Fall Apart? 
06/11The 'Joe Papa' Effect Is Arriving At Valeant 
Financials ($)
Sales 2018 8 499 M
EBIT 2018 3 067 M
Net income 2018 -3 123 M
Debt 2018 23 708 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 3,79x
EV / Sales 2019 3,67x
Capitalization 8 462 M
Chart VALEANT PHARMACEUTICALS IN
Duration : Period :
Valeant Pharmaceuticals In Technical Analysis Chart | VRX | CA91911K1021 | 4-Traders
Technical analysis trends VALEANT PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 16,9 $
Spread / Average Target -31%
EPS Revisions
Managers
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive Vice President
Jerzy Janeczko Head-Information Technology
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VALEANT PHARMACEUTICALS INTL INC25.08%8 462
JOHNSON & JOHNSON-13.17%325 398
PFIZER-0.17%211 520
NOVARTIS-8.25%188 977
ROCHE HOLDING LTD.-14.38%182 331
MERCK AND COMPANY8.46%164 082